

Serial No. 9/674,815  
5836-01-MJA

Please replace all prior claims in the application with the following:

Claims 1-24 (canceled)

Claim 25 (new): A composition of matter comprising a pharmaceutical dosage form, wherein the pharmaceutical dosage form includes:

- (a) an  $\alpha$  amino acid;
- (b) an optional auxiliary agent for manufacturing the pharmaceutical preparation; and
- (c) a 4-amino-3-substituted-butanoic acid derivative selected from gabapentin, pregabalin, 3-aminomethyl-4-cyclohexyl-butanoic acid, 3-aminomethyl-5-cyclohexyl-pentanoic acid, 3-aminomethyl-4-phenyl-butanoic acid, and 3-aminomethyl-5-phenyl-pentanoic acid.

Claim 26 (new): The composition of Claim 25 wherein the  $\alpha$ -amino acid is one or more selected from:

- L-, D- and DL-forms of neutral  $\alpha$ -amino acids;
- alkali salts, acid amides, alkyl-substituted derivatives of acid amides or alkyl esters of the L-, D- and DL-forms of acidic  $\alpha$ -amino acids;
- acid addition salts or monoacylated derivatives of the L-, D- and DL-forms of basic  $\alpha$ -amino acids;
- $\alpha,\omega$ -diaminodicarboxylic acids; and
- acidic amino acid-basic amino acid adducts of the L-, D- and DL-forms of acidic  $\alpha$ -amino acids and the L-, D- and DL-forms of basic  $\alpha$ -amino acids.

Claim 27 (new): The composition of Claim 25 wherein the  $\alpha$ -amino acid is one or more selected from:

- neutral  $\alpha$ -amino acids consisting of glycine, phenylglycine, hydroxyphenylglycine, dihydroxyphenylglycine, L-alanine, hydroxy-L-alanine, L-leucine, hydroxy-L-leucine, dihydroxy-L-leucine, L-norleucine, methylene-L-norleucine, L-ketonorleucine, L-

(After Final Amendment—page 2 of 8)

Serial No. 9/674,815  
5836-01-MJA

isoleucine, hydroxy-L-isoleucine, dihydroxy-L-isoleucine, L-valine, hydroxy-L-valine, L-isovaline, L-norvaline, hydroxy-L-norvaline, hydroxy-L-ketonorvaline, L-methionine, L-homomethionine, L-ethionine, L-threonine, acetyl-L-threonine, L-tryptophan, hydroxy-L-tryptophan, methyl-L-tryptophan, L-tyrosine, hydroxy-L-tyrosine, methyl-L-tyrosine, bromo-L-tyrosine, dibromo-L-tyrosine, 3,5-diido-L-tyrosine, acetyl-L-tyrosine, chloro-L-tyrosine, L-m-tyrosine, L-levodopa, L-methyldopa, L-thyroxine, L-serine, acetyl-L-serine, L-homoserine, acetyl-L-homoserine, ethyl-L-homoserine, propyl-L-homoserine, butyl-L-homoserine, L-cystine, L-homocystine, methyl-L-cysteine, allyl-L-cysteine, propyl-L-cysteine, L-phenylalanine, dihydro-L-phenylalanine, hydroxymethyl-L-phenylalanine, L-aminobutyric acid, L-aminoisobutyric acid, L-ketoaminobutyric acid, dichloro-L-aminobutyric acid, dihydroxy-L-aminobutyric acid, phenyl-L-aminobutyric acid, L-aminovaleric acid, L-aminohydroxyvaleric acid, dihydroxy-L-aminovaleric acid, L-aminoisovaleric acid, L-aminohexanoic acid, methyl-L-amino hexanoic acid, L-aminoheptanoic acid, L-aminoctanoic acid and citrulline and the D- and DL-forms thereof;

acidic  $\alpha$ -amino acids consisting of L-aspartic acid, L-glutamic acid, L-carbocysteine, L-aminoglutamic acid, L-aminosuccinic acid, L-amino adipic acid, L-aminopimelic acid, hydroxy-L-aminopimelic acid, methyl-L-aspartic acid, hydroxy-L-aspartic acid, methyl-L-glutamic acid, methyl-hydroxy-L-glutamic acid, L-methyleneglutamic acid, hydroxy-L-glutamic acid, dihydroxy-L-glutamic acid and hydroxy-L-amino adipic acid and the D- and DL-forms thereof;

basic  $\alpha$ -amino acids consisting of L-arginine, L-lysine, L-ornithine, L-canavanine, L-canagine, hydroxy-L-lysine, L-homoarginine, hydroxy-L-homoarginine, hydroxy-L-ornithine, L-diaminopropionic acid, L-diaminohexanoic acid, L-diaminobutyric acid, L-diaminovaleric acid, L-diaminoheptanoic acid, and L-diaminoctanoic acid and the D- and DL-forms thereof; and

$\alpha,\omega$ -diaminodicarboxylic acids consisting of diaminosuccinic acid, diaminoglutamic acid, diamino adipic acid and diaminopimelic acid;

(After Final Amendment—page 3 of 8)

provided that, when said  $\alpha$ -amino acid is an adipic  $\alpha$ -amino acid, it is used in the form of the corresponding alkali salt, acid amide, alkyl-substituted derivative of acid amide or alkyl ester thereof, or

when said  $\alpha$ -amino acid is a basic  $\alpha$ -amino acid, it is used in the form of the corresponding acid addition salt or monoacylated derivative thereof, or

said acidic  $\alpha$ -amino acid and said basic  $\alpha$ -amino acid are also used in the form of the corresponding acidic amino acid-basic amino acid adduct.

Claim 28 (new): The composition of Claim 25 wherein a total amount of the  $\alpha$ -amino acid is in the range of 0.001 - 80 moles per mole of the 4-amino-3-substituted-butanoic acid derivative.

Claim 29 (new): The composition of Claim 25 wherein the pharmaceutical dosage form is a liquid.

Claim 30 (new): The composition of Claim 25 wherein the pharmaceutical dosage form is a solid.

Claim 31 (new): The composition of Claim 25 wherein the 4-amino-3-substituted-butanoic acid derivative is gabapentin.

Claim 32 (new): The composition of Claim 25 wherein the 4-amino-3-substituted-butanoic acid derivative is pregabalin.

(After Final Amendment—page 4 of 8)